Targeting chromatin modifying complexes in acute myeloid leukemia

Area of Science:

• Hematologic Oncology
• Epigenetics
• Chromatin Biology

Background:

• Acute myeloid leukemia (AML) is characterized by high relapse rates, often linked to epigenetic dysregulation.
• Aberrant histone modifications promote self-renewal gene expression in hematopoietic progenitors, driving leukemogenesis, particularly in MLL-rearranged (MLL-r) and NPM1-mutated AML.
• Menin-KMT2A and polycomb repressive complexes (PRC1/2) are key regulators of these histone modifications and are implicated in AML progression.

Purpose of the Study:

• To review recent findings on how leukemic cells exploit chromatin regulatory complexes for disease progression.
• To discuss the therapeutic potential of targeting menin-KMT2A and PRC1/2 complexes in AML.
• To explore novel combination therapies to address resistance to current monotherapies.

Main Methods:

• Literature review of recent discoveries in AML epigenetics and chromatin regulation.
• Analysis of preclinical and clinical studies on inhibitors targeting menin-KMT2A and PRC1/2 complexes.
• Exploration of therapeutic strategies targeting broader interacting networks of these complexes.

Main Results:

• Leukemic cells hijack menin-KMT2A and PRC1/2 complexes, along with other chromatin regulators, to promote AML.
• Inhibitors targeting these complexes have shown therapeutic efficacy in preclinical and clinical settings.
• Understanding these interactions is crucial for developing effective AML treatments.

Conclusions:

• Targeting menin-KMT2A and PRC1/2 complexes represents a promising therapeutic avenue for AML.
• Novel combination therapies targeting the broader interacting networks of KMT2A and PRC1/2 are needed to overcome treatment resistance.
• Further research into epigenetic mechanisms driving AML is essential for improving patient outcomes.